Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.53 |
| ▸ | MAP3K20 | Q9NYL2 | 4/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.53 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.53 |
| ▸ | MINK1 | Q8N4C8 | 3/20 | 0.53 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.53 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.53 |
| ▸ | FRK | P42685 | 2/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.53 |
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.53 |
| ▸ | CSNK1G3 | Q9Y6M4 | 2/20 | 0.53 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.53 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.53 |
| ▸ | BRAF | P15056 | 14/20 | 0.51 |
| ▸ | RAF1 | P04049 | 8/20 | 0.51 |
| ▸ | EGFR | P00533 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12023720 | 0.86 | FGFR1 (0.57) | FGFR1MAPK8MAP3K20PRKD3MAP4K4 | |
| SCHEMBL12023739 | 0.83 | PRKD3 (0.59) | FGFR1MAPK8MAP3K20PRKD3MAP4K4 | |
| SCHEMBL12023711 | 0.82 | BRAF (0.53) | FGFR1MAPK8MAP3K20PRKD3MAP4K4 | |
| SCHEMBL12023713 | 0.82 | BRAF (0.57) | FGFR1MAPK8MAP3K20PRKD3MAP4K4 | |
| SCHEMBL12024043 | 0.82 | FGFR1 (0.68) | FGFR1MAPK8MAP3K20PRKD3MAP4K4 | |
| SCHEMBL12023259 | 0.82 | BRAF (0.52) | FGFR1MAPK8MAP3K20PRKD3MAP4K4 | |
| SCHEMBL14392171 | 0.78 | TEK (0.63) | FGFR1MAPK8MAP3K20PRKD3MAP4K4 | |
| SCHEMBL13920817 | 0.77 | BRAF (0.48) | FGFR1MAPK8MAP3K20PRKD3MAP4K4 | |
| SCHEMBL12023937 | 0.77 | BRAF (0.53) | FGFR1MAPK8MAP3K20PRKD3MAP4K4 | |
| SCHEMBL12023708 | 0.76 | FGFR1 (0.57) | FGFR1MAPK8MAP3K20PRKD3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301160-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301160-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-7902192-B2 | Inhibitors of P38 and methods of using the same | ARQULE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902192-B2 | Inhibitors of P38 and methods of using the same | ARQULE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | MAPK1, MAPK8, MAPK7 | FGFR1 693/4885MAPK8 2/4885MAP3K20 14/4885 |
| US-20110301160-A1 | Inhibitors of P38 and Methods of Using the Same | MAPK1, MAPK7, MAPK8 | FGFR1 683/4885MAPK8 3/4885MAP3K20 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.